Bridging Innovators: Wallonia-UK Advanced Therapies Mission 2024

30 Sept – 3 Oct 2024 | United Kingdom

Benjamin DAMIEN

CEO

SAGITTA BIOTECH

Liège, Liège, Belgium

1 profile visit

Sagitta Biotech is a company developing vaccines, oncology and gene therapy products from an hybrid Viral Vector/mRNA plaftorm

About

Develops innovative vaccines against infectious diseases and cancer. A ground-breaking proprietary platform which is a hybrid between viral vectors and mRNA techs. The platform is using a highly modified measles-derived vector, capable of expressing up to 6 antigens on the surface of a virosome, but also capable of delivering a self-replicating mRNA into target cells.

My organisation

Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.

Sagitta's innovative platform is based on a reverse-engineering of the Measles virus, able to express up to 6 different antigen on its surface (including affinity proteins to infect cells carrying specific markers) and to deliver a self-replicating RNA in the cells.

The technology is being used to develop multivalent vaccines, oncology products or gene therapy vectors. We are looking for partners to evaluate our technology as a way to modify cells in vitro or in vivo (CAR T cell generation in vivo).

Social media

Skills

  • vaccines
  • Immunology
  • oncology
  • Molecular Biology
  • Management
  • corporate funding

Interests

  • Funding
  • deal making
  • startups

Marketplace (1)